Latest Healthcare News

nib Group reported solid FY25 results with revenue growth to $3.6 billion and a 9.4% rise in net profit after tax, while maintaining its full-year dividend at 29 cents per share. The company’s Australian private health insurance business achieved record policyholder growth amid ongoing claims inflation and operational efficiencies.

nib holdings limited reported a 9.4% increase in net profit after tax to $198.6 million for FY25, alongside a 7.8% rise in group revenue to $3.6 billion. Despite a dip in underlying operating profit, the company declared a fully franked final dividend, maintaining its full-year payout at 29 cents per share.

Vita Life Sciences delivered a robust first half in 2025 with record revenue and profit growth, driven by strong performances in Australia and Southeast Asia. The company also raised its interim dividend and expanded marketing efforts.

Vita Life Sciences reported a robust half-year performance with revenue up 15.4% to A$45.5 million and a 12.2% rise in net profit, driven by strong growth in Australia and Southeast Asia. The company also increased its interim dividend to 4.5 cents per share, signaling confidence despite challenges in China.

Ansell Limited reported record FY25 sales and EBIT margins, completing KBU integration ahead of schedule and upgrading synergy targets. The company guides higher adjusted EPS for FY26, fully offsetting US tariff hikes through pricing.

Ansell Limited has announced an unfranked ordinary dividend of USD 0.28 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan available to select shareholders.

Universal Biosensors Inc. has been suspended from ASX trading following the appointment of voluntary administrators, highlighting serious financial distress within the company.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.

Monash IVF Group reported a 5.6% rise in underlying EBITDA for FY25, navigating a declining Australian IVF market and operational challenges. The company sets a cautious FY26 NPAT guidance of $20-23 million while focusing on regaining market leadership and implementing safety reforms.

Monash IVF Group reported steady FY25 financial results with revenue and EBITDA growth, while managing clinical incidents and a CEO transition. The company outlines cautious FY26 guidance amid industry headwinds.

Monash IVF Group reported a 6.7% revenue increase to $271.9 million in FY25 but saw an 8.1% decline in underlying net profit after tax to $27.4 million, impacted by market softness and operational incidents. The company outlines cautious FY26 guidance amid ongoing sector headwinds.